24/7 Market News Snapshot 17 April, 2025 – Clearmind Medicine Inc. Common Shares (NASDAQ:CMND)

April 17, 2025

DENVER, Colo., 17 April, 2025 (www.247marketnews.com) – (Nasdaq:CMND) are discussed in this article.
Clearmind Medicine Inc. ( Nasdaq:CMND) has recently attracted significant attention in the market, with shares surging 26.29% to $1.225 during the pre-market session, a notable rise from the prior close of $0.970. This upward momentum is accompanied by robust trading activity, reflected in a volume of 2.05 million shares, indicating heightened investor interest and confidence in the company’s strategic direction.

Contributing to this positive shift, Clearmind has announced a major achievement in its efforts to develop innovative psychedelic-derived therapeutics. The United States Patent Office has granted a Notice of Allowance for Clearmind’s MEAI treatment, which targets binge behavior. This patent represents a critical advancement in the company’s intellectual property portfolio and strengthens its competitive position in the burgeoning psychedelic medicine sector.

Dr. Adi Zuloff-Shani, CEO of Clearmind, expressed the significance of this development: “This Notice of Allowance further reinforces our unique standing in the industry and enhances our expanding intellectual property portfolio. Securing foundational patent protection is a vital step in supporting our future success and in advancing the development of next-generation psychedelic-derived therapeutics that have the potential to transform patient outcomes.”

With a roster of nineteen patent families and 31 granted patents, Clearmind is dedicated to pioneering treatments for prevalent health issues, including alcohol use disorder. The company is focused on exploring the commercialization of its psychedelic-based compounds as regulated medicines, foods, or supplements. Looking ahead, Clearmind intends to pursue further patents, thereby enhancing its intellectual asset base.

As Clearmind continues to innovate within the psychedelic pharmaceutical landscape, shares are actively traded on Nasdaq under the symbol “CMND” and on the Frankfurt Stock Exchange under the symbol “CWY0.” The recent patent allowance not only marks a significant milestone for the company but also sets the groundwork for future advancements in psychedelic therapy, demonstrating Clearmind’s commitment to positively impacting global patient outcomes.

Related news for (CMND)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.